Department of Cardiology, Dayi County People's Hospital, Chengdu, Sichuan, China.
Department of Medical Laboratory, Dayi County People's Hospital, Chengdu, Sichuan, China.
Medicine (Baltimore). 2023 Oct 13;102(41):e35612. doi: 10.1097/MD.0000000000035612.
The coronavirus disease 2019 infection has significantly impacted the world and placed a heavy strain on the medical system and the public, especially those with cardiovascular diseases. Hoverer, the differences in door-to-balloon time and outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not known too much.
Web of Science, EMBASE, PubMed, Cochrane Library, Wanfang, VIP, and China's National Knowledge Infrastructure were utilized to perform a systematic literature search until April 30, 2023. We computed the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) to determine the correlation. A random-effects model was used for the meta-analysis if the study had significant heterogeneity. Meanwhile, sensitivity analysis and Trial sequential analysis were also accomplished using Rveman5.4 and trial sequential analysis 0.9.5.10 Beta software, respectively.
A total of 5 eligible studies were explored in our meta-analysis, including 307 cases and 1804 controls. By meta-analysis, the pooled data showed that SARS-CoV-2-positive STEMI patients undergoing percutaneous coronary intervention had a longer door-to-balloon time (OR 6.31, 95% CI 0.99, 11.63, P = .02) than the negative subjects. The glycoprotein IIb/IIIa inhibitor use after SARS-CoV-2 infection (OR 2.71, 95% CI 1.53, 4.81, P = .0006) was relatively frequent compared with controls, and the postoperative Thrombolysis in Myocardial Infarction blood flow (OR 0.48, 95% CI 0.34, 0.67, P < .0001) was worse compared that. The in-hospital mortality (OR 5.16, 95% CI 3.53, 7.53, P < .00001) was higher than non-SARS-CoV-2 infection ones. In addition, we also discovered that age, gender (male), hypertension, diabetes mellitus, hyperlipidemia, smoking, previous myocardial infarction, total ischemia time, and thrombus aspiration use did not have a significant association with the development of STEMI patients with SARS-CoV-2.
SARS-CoV-2 positivity is significantly associated with longer door-to-balloon time and higher in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention.
2019 年冠状病毒病的感染对世界产生了重大影响,对医疗系统和公众造成了巨大压力,尤其是心血管疾病患者。然而,人们对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染后接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死(STEMI)患者的门球时间和结局差异知之甚少。
我们使用 Web of Science、EMBASE、PubMed、Cochrane Library、万方、VIP 和中国国家知识基础设施进行了系统的文献检索,检索时间截至 2023 年 4 月 30 日。我们计算了比值比(OR)及其相应的 95%置信区间(CI)来确定相关性。如果研究存在显著异质性,则采用随机效应模型进行荟萃分析。同时,还使用 Rveman5.4 和 trial sequential analysis 0.9.5.10 Beta 软件分别进行敏感性分析和试验序贯分析。
我们的荟萃分析共纳入了 5 项符合条件的研究,包括 307 例病例和 1804 例对照。荟萃分析结果表明,SARS-CoV-2 阳性 STEMI 患者行经皮冠状动脉介入治疗的门球时间较长(OR 6.31,95%CI 0.99,11.63,P=0.02)。与对照组相比,SARS-CoV-2 感染后使用糖蛋白 IIb/IIIa 抑制剂更为常见(OR 2.71,95%CI 1.53,4.81,P=0.0006),术后心肌梗死溶栓血流(OR 0.48,95%CI 0.34,0.67,P<0.0001)较差。住院死亡率(OR 5.16,95%CI 3.53,7.53,P<0.00001)高于非 SARS-CoV-2 感染组。此外,我们还发现年龄、性别(男性)、高血压、糖尿病、高血脂、吸烟、既往心肌梗死、总缺血时间和血栓抽吸术的使用与 SARS-CoV-2 感染的 STEMI 患者的发展没有显著相关性。
SARS-CoV-2 阳性与 STEMI 患者直接经皮冠状动脉介入治疗后门球时间延长和住院死亡率升高显著相关。